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Abstract
Background—Both diabetes and antidiabetic drugs (ADDs) increase the risk for cardiovascular
(CV) diseases. Due to the increasing concern about CV safety associated with ADDs, the US FDA
revised regulatory guidelines in 2008 to include CV safety as an endpoint.
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Objective—The objective of the current study was to conduct a systematic review with metaanalysis to compare CV mortality of oral ADDs approved before and after the FDA’s 2008
guidance.
Methods—Three electronic databases (PubMed, Scopus, and the Clinical Trial Registry) were
searched to retrieve studies published up to 24 February 2017. Randomized clinical trials were
included in this study if they (1) were published in the English language; (2) included adults with
type 2 diabetes mellitus with or without CV risk factors, who were taking at least one oral
antidiabetic drug; and (3) had at least one study outcome as CV mortality. Meta-analysis was
performed using a random-effects model. Small-study effects were accessed using funnel plot
symmetry. The primary outcome was CV mortality.
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Results—We found that there was no significant increase in CV mortality for drugs approved
before and after 2008. The overall odds ratio (OR) and the upper bound of the two-sided 95%
confidence interval (CI) for all drugs approved after 2008 (OR 0.74, 95% CI 0.52–1.07) were
lower than the overall OR for all drugs approved before 2008 (OR 1.03, 95% CI 0.89–1.19). In
addition, the upper bounds of the two-sided 95% CI for both groups of drugs before and after 2008
were below 1.3. Empagliflozin, which was approved after the guidance, was significantly
associated with a reduction in CV mortality.
Conclusion—The 2008 FDA guidance appears to have a positive impact on CV risk assessment
of recently marketed drugs for the management of diabetes.

1 Introduction
Author Manuscript

In 2015, there were 30.3 million people with diabetes in the US, which accounted for 9.4%
of the population [1]. The estimated cost of treating diabetes in 2012 was $245 billion [1].
Type 2 diabetes mellitus (T2DM) is considered a controllable risk factor for cardiovascular
(CV) diseases [2]. Adults with T2DM are two- to fourfold more likely to have a heart attack
or stroke [2]. T2DM also increases CV mortality by more than twofold [3].
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The management and maintenance of glycemic control is one of the most important
components of diabetes treatment [4–6]. The association between glycated hemoglobin
(HbA1c) control and reduction in microvascular complications is well established [7, 8];
however, there are mixed results for the association between HbA1c management, especially
for the use of antidiabetic drugs (ADDs) and macrovascular complications. A recent study
by Currie et al. showed a significant association between HbA1c and CV mortality [9].
According to this study, with every 1% increase in the HbA1c, the risk of CV mortality
increased 1.15-fold [10]. On the contrary, several randomized clinical trials (RCTs),
including the United Kingdom Prospective Diabetes Study, have failed to show any
significant association between glycemic control and reduction in the risk of macrovascular
complications [11, 12]. Patients with T2DM have a higher risk of developing CV
complications (both micro- and macrovascular) and their risk increases with an increase in
HbA1c level; however, it remains unclear whether the use of ADDs to control HbA1c is
associated with reduced macrovascular complications. Recent findings called into question
the CV safety of ADDs [8, 13–18]. For example, rosiglitazone users were observed to have a
higher risk of heart attacks, strokes, and CV mortality [19]. Dipeptidyl peptidase-4 (DPP-4)
inhibitors were also shown to be associated with decreased hospitalization due to heart
failure in one study [20], while another study reported a higher rate of hospitalization due to
heart failure among those using DPP-4 inhibitors [17].
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Prior to 2008, the manufacturers of ADDs were only required to provide evidence for drug
efficacy in terms of reducing HbA1c levels for gaining market access; however, this criterion
led to the inclusion of only low-risk people, who were less likely to have any CV
complications, in premarketing clinical trials [21]. Moreover, reduction in fasting blood
glucose or improvement in lipids was sometimes used as a surrogate endpoint to predict CV
events in clinical trials on ADDs approved before 2008. Unfortunately, some ADDs
approved before 2008 were later found to be associated with increased risks of CV events.
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Given the high uncertainty around CV safety of ADDs, the US FDA issued the ‘Guidance
for Industry: Diabetes Mellitus—Evaluating Cardiovascular Risk in New Antidiabetic
Therapies to Treat Type 2 Diabetes’ in 2008 [22, 23]. The 2008 FDA guidance recommends
conducting clinical trials to assess CV death, myocardial infarction, and stroke, as well as
hospitalization for acute coronary syndrome and urgent revascularization procedures as
endpoints. These outcomes are generally referred to as major adverse CV events (MACEs).
New ADDs need to prove that the CV risk is within an acceptable range of increase by
demonstrating the upper bound of the two-sided 95% confidence interval (CI) of the risk
ratio of MACEs < 1.8. If the upper bound of the two-sided 95% CI of the risk ratio is
between 1.3 and 1.8, a postmarketing clinical trial will be needed to ensure the upper bound
of the two-sided 95% CI of the risk ratio is below 1.3.
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Healthcare professionals were enthusiastic about the influence of this guidance and had
hoped that safer and effective drugs would come to market [24]. Most of the clinical trials in
the past included those patients who were at lower risk for CV complications. However, the
2008 FDA guidance suggested the inclusion of high-risk patients as well, such as elderly and
those with advanced disease and renal impairment [24]. This 2008 FDA guidance is
intended to bring to the market drugs that do not increase the risk of CV diseases. In fact,
after 2008, we have newly approved ADDs showing CV benefits. However, there has not yet
been a comprehensive evaluation of intended and unintended impacts of the 2008 FDA
guidance on CV-related outcomes in diabetes drug development [25].
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The increasing global incidence and prevalence of T2DM coupled with the CV
consequences associated with both T2DM and ADDs represent an international public
health crisis, demanding higher levels of certainty and evidence on how to safely and
effectively treat these patients. We therefore conducted a systematic review with metaanalysis to compare CV mortality of ADDs approved for market before and after the 2008
FDA Guidance for Industry. Our hypothesis was that the ADDs approved after the release of
the FDA’s 2008 Guidance for Industry will have lower risks of CV mortality compared with
those that were approved before 2008.

2 Methods
2.1 Study Eligibility
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Study eligibility was decided a priori. Studies with the following characteristics were
included in the meta-analysis: (1) adults with T2DM with or without CV risk factors; (2)
participants taking at least one oral ADD; (3) at least one study outcome on CV mortality;
(4) RCTs; and (5) studies published in the English language up until 24 February 2017. We
included studies that explicitly reported CV mortality. In addition, to reduce the
heterogeneity of the study population, we only included oral ADDs. Because insulin and
other injectable drugs are generally not used as first-line therapies for T2DM, they are
generally prescribed for patients who cannot achieve appropriate glucose levels with other
therapies.
The ADDs were classified into two groups: drugs approved before the 2008 FDA Guidance
for Industry and those approved after the 2008 FDA guidance. The search was limited to
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articles published in peer-reviewed journals. The unpublished literature was not searched
because of the difficulty in retrieving them and the uncertainty about the quality of their
study designs.
2.2 Data Sources
We retrieved the literature from the following sources: (1) PubMed; (2) Scopus; and (3) the
Clinical Trial Registry (ClinicalTrials.gov). The exact search strategy varied based on the
database searched, however basic search terms included ‘type-2 diabetes’, ‘drug class’,
‘cardiovascular mortality’, and ‘random*’. An image of the search strategy is included in
Online Resource eFig. 1. All duplicate studies were discovered and deleted using the ‘Find
Duplicates’ tool in Endnote® 7.4, as well as through manual examination by the first author
(RG), while all nonduplicate studies were stored in Endnote® version 7.4. All searches were
performed by the first author (RG).
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2.3 Study Selection
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After removing the duplicate studies, study selection was performed by the first (RG) and
second (PR) authors independent of each other by reviewing the title and abstract. The full
text of the studies was retrieved for all titles and abstracts that appeared to meet the inclusion
criteria or where there was any uncertainty. Reasons for exclusion were characterized as one
or more of the following: inappropriate population, inappropriate intervention, inappropriate
comparison, inappropriate outcome(s), and inappropriate study design. After selection, the
first and second authors reviewed their selections and resolved any discrepancies by
consensus. If consensus could not be reached, two other authors (JC, XT) were consulted.
The overall agreement rate before correcting discrepant items was calculated using Cohen’s
kappa statistic (κ). Once discrepancies were resolved, the overall precision of searches was
calculated by dividing the number of studies included by the total number of studies
screened after removing duplicates. The number needed to read (NNR) was then calculated
as the inverse of precision.
2.4 Data Abstraction
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Before data abstraction, a detailed codebook was developed in Microsoft Excel® 2013
(Microsoft Corporation, Redmond, WA, USA). The general categories for which the
included studies were coded comprised: (1) study participant characteristics; (2) study
intervention regimens (drug dose, route of administration, and frequency); (3) study control
(oral ADDs or placebo), with control also coded for dose, route of administration and
frequency; (4) primary outcome (CV mortality); (5) study design; and (6) source of funding.
The first two authors (RG, PR) performed data abstraction from selected studies,
independent of each other, using the codebook in Microsoft Excel® 2013. Upon completion,
both authors reviewed the codebook and resolved discrepancies by consensus. If consensus
could not be reached, two other authors (JC, XT) were consulted. Before correcting
disagreements, the overall agreement rate was calculated using Cohen’s kappa statistic (κ).
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2.5 Outcomes and Prioritization
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The primary outcome was CV mortality. As aforementioned, there is no consensus on the
relation of HbA1c with CV mortality. Therefore, the secondary outcome was HbA1c levels.
2.6 Risk of Bias Assessment in Individual Studies

Author Manuscript
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The risk of bias was assessed using the Cochrane Risk of Bias instrument [26]. Bias was
evaluated for six domains: (1) random sequence generation (clinical trials usually assign
study subjects to the treatment and control groups randomly to minimize selection bias and
to ensure that the groups are comparable. The first domain of the risk of bias instrument
evaluated whether the study subjects were randomly assigned to the treatment groups); (2)
allocation concealment (the allocation of treatment is often performed using a computergenerated or otherwise randomized sequence. The second domain was used to evaluate
whether the sequence or method used for treatment allocation was concealed from patients,
researchers, or any other study personnel); (3) blinding of participants and personnel (a lot
of clinical trials have a double-blind study design to conceal the treatment from study
subjects and the researcher to minimize selection bias. If the study was blinded, the third
domain was used to evaluate whether the study subjects and the personnel involved were
blinded); (4) blinding of outcome assessors (the fourth domain was used to evaluate if the
person assessing the primary outcomes was blinded or not. All participants who are enrolled
in the study often do not complete the study; the extent to which the authors had described
the loss of participants to follow-up, along with the reason for the loss to follow-up, was
used to determine whether there was any attrition bias or not); (5) incomplete outcome data;
and (6) selective reporting (selective reporting bias was used to assess the consideration of
the possibility of selective outcome reporting by the review authors). Each study was
classified as having a high, low, or unclear risk of bias both overall and for each domain. The
overall risk of bias was classified as high if any one of the domains was considered high risk.
No study was excluded based on the results of the risk of bias assessment. The first two
authors (RG, PR) conducted all risk of bias assessments independent of each other, and then
reviewed the results for risk of bias assessment and resolved any discrepancies by consensus.
If consensus could not be reached, two other authors (JC, XT) were consulted.

3 Data Synthesis
3.1 Outcome Summary Measures

Author Manuscript

The primary outcome for this study was CV mortality, calculated as an odds ratio (OR). All
analyses were conducted by using the natural log of the OR and then transformed back to
ORs for presentation purposes. If the OR was not reported, then it was calculated from data
reported in the study. If data were not available to calculate the OR, then we contacted the
study authors and requested relevant data. The secondary outcome was reported as
standardized mean difference, calculated by dividing the change in mean baseline HbA1c
and standard deviation (SD).
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3.2 Pooled Estimates for Changes in Outcomes
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Effect size changes in both CV mortality and HbA1c were pooled using the random-effects
model [27]. Heterogeneity for each pooled outcome was estimated using Cochran’s Q [28,
29]. An alpha level of ≤ 0.10 for Q was considered to represent statistically significant
heterogeneity. Inconsistency, which was estimated using the I2 statistic, was categorized as
very low (≤ 25%), low (25% to ≤50%), moderate (50% to ≤ 75%) or large (≥ 75%) [29].
Influence analysis was conducted with each study deleted from the model once, to examine
the effect of each study on our overall results. In addition, cumulative meta-analysis, ranked
by year, was used to study the accumulation of results over time. Subgroup analysis was
performed to examine the association between CV mortality and the year in which a drug
was approved by the FDA.
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3.3 Meta-Biases
Small-study effects (publication bias, etc.) for the primary and secondary outcomes were
assessed using a funnel plot [30], which is a scatter plot of the effect estimates from
individual studies against precision (inverse of standard error). The effect estimates from
smaller studies scatter at the bottom and larger studies are concentrated at the top. The plot
resembles a symmetrical inverted funnel in the absence of bias.

4 Results
4.1 Study Characteristics

Author Manuscript
Author Manuscript

Table 1 presents the general description of the characteristics of each of the included studies.
Of the 392 citations reviewed, a total of 54,951 participants (27,670 in the oral ADD groups
and 27,281 in the control groups) nested within ten studies were included in the final
analysis [20, 31–39]. All ten studies were used in the qualitative analysis, whereas only
seven studies were included in the quantitative analysis due to incomplete reporting. The
three studies that were not included in the quantitative analysis did not report data to
calculate an effect size for CV mortality. The precision of the searches was 0.02 and the
NNR was 39. A description of the study selection process, along with the number of studies
screened, included, and excluded, and broad categories of reason for exclusion, are
presented in Fig. 1. A list of excluded studies along with reasons for exclusion is provided in
Online Resource eTable 1. The number of subjects in each class of drug from each study
varied from 151 to 8280. Among the studies included in the systematic review, one was
conducted in the US, one in the UK, one in China, and seven studies were carried out in
multiple countries simultaneously. The average follow-up period was 3.9 years (SD ± 2.6,
median 3.05 years, range 0.5–5.7 years). Six studies included in the systematic review had
an active comparator (either an oral ADD or insulin) and four studies were placebo
controlled. The included studies accessed four different classes of drug that were approved
before 2008: biguanides (metformin), thiazolidinediones (pioglitazone and rosiglitazone),
sulfonylureas (glipizide, chlorpropamide, glibenclamide, glyburide, and glimepiride), DPP-4
inhibitor (sitagliptin); and two drug classes that were approved after 2008: DPP-4 inhibitor
(linagliptin, and saxagliptin) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors
(empagliflozin).
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4.2 Participant Characteristics
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Characteristics of the participants are also presented in Table 1. The mean ages in the
intervention and control groups were 61.1 years (SD ± 3.8) and 61.6 years (SD ± 3.2),
respectively, and the mean baseline HbA1c level in the intervention group was 7.7% (SD
± 0.7), and 7.8% (SD ± 0.7) in the control group.
4.3 Primary Outcome
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The forest plot of CV mortality of oral ADDs is shown in Fig. 2. When including all oral
ADDs (both approved before and after 2008) into the analyses, there was no significant
increase in the risk of CV mortality, and the upper bound of the two-sided 95% CI of the OR
was < 1.3 (OR 0.85, 95% CI 0.68–1.06). The results from the influence analysis revealed a
similar conclusion, with ORs for CV mortality ranging between 0.80 (95% CI 0.62–1.05)
and 0.92 (95% CI 0.76–1.12). The pooled effect size, Cochran’s Q statistics, I squared
statistics, and tau-squared are presented in Table 2.
When comparing the risks of CV mortality between the drugs approved before and after
2008, we found there were no significant increases in CV mortality for both groups of drugs
approved before and after 2008 (Fig. 2). The OR and the upper bound of the two-sided 95%
CI for drugs approved after 2008 (OR 0.74, 95% CI 0.52–1.07) were lower than the OR for
drugs approved before 2008 (OR 1.03, 95% CI 0.89–1.19). Furthermore, the upper bounds
of the two-sided 95% CI for both drugs before and after 2008 were below 1.3.
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The forest plot of CV mortality of oral ADDs by the comparator groups (placebo vs. active
control) is presented in Online Resource eFig. 5. We did not find any significant association
between the risk of CV or mortality of oral ADDs and the studies in which the control group
was an active comparator group (OR 0.91, 95% CI 0.66–1.24) versus those in which the
control group was placebo (OR 0.82, 95% CI 0.61–1.06). The upper bounds of the two-sided
95% CI for drugs in both groups were also within the range prespecified by the FDA in their
2008 Guidance to Industry (below 1.3).

Author Manuscript

The funnel plot is presented in Fig. 3. Minor asymmetry was observed due to small-study
effects. The results from subgroup analysis of examining CV mortality among different drug
classes are shown in Fig. 4. Only the SGLT-2 inhibitor drug class was shown to have a
significant reduction in CV mortality. Both 10 and 25 mg doses of empagliflozin were
associated with a 36 and 42% reduction in CV mortality, respectively, compared with
placebo [36]. All other drug classes did not show a significant increase in CV mortality, but
sulfonylureas had a higher OR of CV mortality and the upper bound of the two-sided 95%
CI of the OR was greater than 1.8, which is outside the limits specified by the FDA [23].
4.4 Secondary Outcome
The forest plot of the efficacy of oral ADDs (HbA1c) is presented in Online Resource eFig.
2. The comparison of the efficacy of oral ADDs approved before (standard mean difference
[SMD] −0.12, 95% CI −0.34 to 0.22) and after 2008 (SMD 0, 95% CI −0.16 to 0.16) did not
show significant differences. In addition, taking all included oral ADDs together (both
approved before and after 2008), we did not find significant reductions in HbA1c (SMD
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−0.08, 95% CI −0.26 to 0.09). The funnel plot (Online Resource eFig. 3) shows minor
asymmetry due to small-study effects. Influence analysis revealed that the SMD of HbA1c
ranged between −0.05 (95% CI −0.22 to 0.16) and −0.16 (95% CI −0.27 to −0.05). The
pooled effect size, Cochran’s Q statistics, I-squared statistics, and tau-squared are all
presented in Table 2.
Another subgroup analysis was performed by assessing the effects on HbA1c among
different ADD classes (Online Resource eFig. 4). We observed a significant decrease in
HbA1c in SGLT-2 inhibitors (empagliflozin 10 mg: SMD −0.24, 95% CI −0.40 to −0.08;
empagliflozin 25 mg: SMD −0.36, 95% CI −0.51 to −0.20). No other drug classes were
found to have a significant influence on HbA1c. A significant reduction in HbA1c was seen
in the studies where baseline HbA1c was > 8% compared with those where baseline HbA1c
was < 8%.

Author Manuscript

4.5 Risk of Bias
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Risk of bias results are shown in Online Resource eFig. 6, while the results for each item
from each study are shown in Online Resource eTable 2. Nine of ten studies [20, 31, 32, 34–
39] were considered to be at low risk on random sequence generation, while one study was
considered to be at high risk [33]. Most the studies (eight of ten) were at low risk [31–35,
37, 39] with respect to allocation concealment, while two studies were considered to be at
high risk [36, 39]. Blinding of participants and personnel was poorly reported; three studies
were considered to be at low risk [34, 37, 38], three at high risk [35, 36, 39], and the
remaining four studies at unclear risk [20, 31–33]. Blinding of outcome assessment was also
poorly reported; two studies were at low risk [34, 38], three studies at high risk [35, 36, 39],
and the remaining five studies at unclear risk [20, 31–33, 37]. On incomplete outcome data
reporting, four studies were considered to be at low risk [32–34, 37], while six studies were
considered to be at high risk [20, 31, 35, 36, 38, 39]. Most of the studies (six of ten) were
considered to be at low risk [20, 32–34, 36, 38] on selective reporting, while four studies
were considered to be at high risk [31, 35, 37, 39].

5 Discussion
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To the best of our knowledge, this was the first study to evaluate whether or not the
implementation of the 2008 FDA guidance resulted in the approval of ADDs with a safer
CV profile. We did not find significant increases in CV mortality for both groups of drugs
approved before and after 2008, and the ORs of both groups were within the acceptable
range. Nonetheless, the group of drugs that were approved before 2008 was edging on a
higher risk of CV mortality, with a higher OR and upper bound of the two-sided 95% CI,
compared with the group approved after 2008. After 2008, we have approved drugs with
significant reductions in CV mortality [25].
We did not find a significant increase in CV mortality for drugs approved before 2008, and
the upper bound of the two-sided 95% CI of the overall OR in this group was also in the
acceptable range; however, this should be interpreted in the following context. First, since
manufacturers were only required to prove efficacy before the implementation of the
guideline, there are only a few clinical trials evaluating the CV safety of the ADDs that were
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approved before 2008. Second, clinical trials of drugs that were approved before 2008
included more low-risk patients. For example, the study by Hong et al. included patients
with a low or properly managed HbA1c, who had normal body mass index, and were mostly
males [34]. Therefore, these were low-risk patients who were less likely to develop any CV
complications with or without oral ADDs. Third, the non-significant results from RCTs of
the drugs approved before 2008 could be attributed to the relatively short duration of followup or the small sample size. The RCTs that had CV mortality or CV safety as an endpoint
either had a short follow-up of < 1 year [32, 33] or a small sample size [35], which may be
potential barriers to establishing significance.
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In addition, the purpose of the FDA guidance of 2008 was not only to have specific CV
endpoints to evaluate the CV safety of the ADD but was also to emphasize that HbA1c could
not be used as a surrogate of CV safety and is a poor predictor of macrovascular
complications and CV mortality [40]. Our study findings were consistent with the guidance
recommendations. Three studies for drugs approved after 2008 showed a significant
reduction in HbA1c; however, two did not show any significant association with CV
mortality [20, 37, 41]. Nonetheless, a trial using empagliflozin, which was approved after
2008, was shown to have a significant reduction in CV mortality [36], yet the ADD drug
class differences in CV mortality may confound the influences of the 2008 FDA guidance on
CV mortality. Although the overall trend was that drugs approved after 2008 had a safer CV
mortality risk profile than those approved before 2008, it is not certain whether this was
influenced primarily by the FDA 2008 guidance or the effect of the drug class.

Author Manuscript

There are opposing opinions on the implementation of the 2008 FDA guidance. On the one
hand, researchers believe that the 2008 FDA guidance leads to uncovering of unrecognized
CV side effects. In this way, it is thought that the landscape of ADD development has been
radically changed by establishing CV safety, recognizing side effects, and including highrisk populations [21]. On the other hand, some question the application of stricter rules to all
ADD classes. Thus, a more targeted approach was suggested to assess CV safety in new
ADDs [25]. Along with the paradigm shift in the industry to bring drugs with a better CV
safety profile to the market after 2008, our results further strengthen the recommendations of
2008 FDA guidance use for the preapproval stage of ADD development.
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Given the difference in the CV risk profile of different ADD classes, clinicians should weigh
CV safety against the potential benefits in treatment decisions. Our study provides
summarized evidence about the CV mortality of oral ADDs. DPP-4 inhibitors and SGLT-2
(empagliflozin) have a fairly low risk for CV mortality. Clinicians might consider
prescribing ADDs with relatively lower CV risk implications to diabetes patients who have
high risks of developing CVD.
This study has some limitations. Although CV mortality is one of the outcomes suggested by
the FDA to be reported in trials evaluating the CV safety of ADDs, most of the studies report
them as a composite primary endpoint, along with nonfatal myocardial infarction and stroke;
therefore, only a few RCTs report CV mortality individually. Most of the studies included in
our meta-analysis did not adequately report the outcomes. Six of ten studies had a high risk
of bias on incomplete outcome data. All the meta-analyses inherit the weaknesses and
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limitations of the studies that are included for analysis, which can impact the findings and
conclusions drawn from the meta-analysis. Another limitation of a meta-analysis is that it
may be prone to ecological fallacy; since we have used an aggregate data approach in the
current study, drawing inferences for an individual based on the study findings might be
inappropriate.
Despite these limitations, this study is the first meta-analysis evaluating the impact of the
2008 FDA guidance on CV mortality of oral ADDs, comparing the CV mortality of ADDs
approved for market before and after the 2008 FDA guidance. This is a comprehensive
systematic review including ten trials with a total of 54,951 adults with T2DM. We also used
a rigorous method to conduct our meta-analysis (e.g. use of the Cochrane Risk of Bias tool
to assess the risk of bias of the included studies).
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6 Conclusions
Overall, there appears to be a positive influence of the 2008 FDA guidance on CV mortality.
The overall trend was that the drugs approved after 2008 had a safer CV mortality risk
profile than those approved before 2008. Empagliflozin was found to be associated with a
significant reduction in CV mortality. After 2008, there has been a paradigm shift in the
ADD development industry to bring more drugs with a safer CV profile to the market. With
the continued implementation of the 2008 FDA Guidance for Industry, we expect to see
more drugs that do not increase, and even reduce, the risk of CV mortality among these
patients.
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Refer to Web version on PubMed Central for supplementary material.
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Key Points
This is the first study to evaluate the impact of the US FDA’s 2008 guidance to industry
on cardiovascular (CV) mortality of antidiabetes drugs (ADDs).
Our study found that there was no significant increase in CV mortality for drugs
approved before and after 2008.
The 2008 FDA guidance to industry has successfully directed more focus to the CV
safety of ADDs, along with efficacy, thereby resulting in marketing of ADDs with a safer
CV profile.
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Fig. 1.

Study selection process
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Fig. 2.
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Impact of oral hypoglycemic agents on cardiovascular mortality, approved before and after
2008. Forest plot from the randomeffects model for association between oral antidiabetic
drugs and cardiovascular mortality, comparing those approved before and after the 2008
FDA Guidance for Industry. Seven studies were included in the analysis. The results of
Zinman et al. [36] (10 and 25 mg) were from one study where cardiovascular safety of two
different strengths of empagliflozin were assessed. OR odds ratio, CI confidence interval
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Fig. 3.
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Funnel plot for the association between oral antidiabetic drugs and cardiovascular mortality.
Small-study effects are present, as observed by little asymmetry in the plot. The figure
depicts small-study effects of seven studies included for meta-analysis. There are eight data
points in the plot because the results of Zinman et al. [36] (10 and 25 mg) were from one
study where cardiovascular safety of two different strengths of empagliflozin were assessed.
Egger’s bias = − 0.5960166, p = 0.650
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Forest plot from the random-effects model for the association between oral antidiabetic
drugs and cardiovascular mortality, comparing different pharmacological drug classes. The
results of Zinman et al. [36] (10 and 25 mg) were from one study where cardiovascular
safety of two different strengths of empagliflozin were accessed. OR odds ratio, CI
confidence interval
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